
CLAIMS

1. A compound having the Formula (I):




(I)

a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof or an *N*-oxide form thereof, wherein:

R^1 is selected from the group of hydrogen, $-CH_3$ and $-CF_3$;

R^2 and R^3 are each independently selected from the group of hydrogen, halogen, $-(C_1\text{-}C_6)$alkyl, $-(C_1\text{-}C_6)$haloalkyl and $-CF_3$;

P represents a cycloalkyl, aryl, heteroaryl or heterocycle of formula:



wherein each cycloalkyl, aryl, heteroaryl or heterocycle ring is optionally substituted with m radicals A, wherein m is an integer equal to zero, 1, 2, 3 or 4;


wherein Z^1, Z^2, Z^3, Z^4, Z^5, Z^6 and Z^7 are each independently selected from C, N, O or S; provided that at least one of Z^1, Z^2, Z^3, Z^4, Z^5, Z^6 and Z^7 is N;

the or each $(A)_m$ is independently selected from the group of hydrogen, halogen, -CN, -OH, $-NO_2$, $-CF_3$, -SH, $-NH_2$ and an optionally substituted radical selected from the group of -(C_1-C_6)alkyl, -(C_1-C_6)haloalkyl, -(C_2-C_6)alkynyl, -(C_2-C_6)alkenyl, -(C_3-C_7)cycloalkyl, -(C_1-C_6)alkylene-(C_3-C_7)cycloalkyl, -(C_3-C_8)cycloalkenyl, -(C_1-C_6)cyanoalkyl, -(C_1-C_6)alkylene-heteroaryl, -(C_1-C_6)alkylene-aryl, aryl, heteroaryl, -(C_1-C_6)alkylene-heterocycle, heterocycle, -(C_0-C_6)alkylene-OR^4, -O-(C_2-C_6)alkylene-OR^4, $-NR^4$(C_2-C_6)alkylene-OR^5, -(C_3-C_6)alkynylene-OR^4, -(C_3-C_6)alkynylene-NR^4R^5, -(C_3-C_6)alkenylene-OR^4, -(C_3-C_6)alkenylene-NR^4R^5, -(C_0-C_6)alkylene-S-R^4, -O-(C_2-C_6)alkylene-S-R^4, $-NR^4$-(C_2-C_6)alkylene-S-R^5, -(C_0-C_6)alkylene-S(=O)-R^4, -O-(C_1-C_6)alkylene-S(=O)-R^4, $-NR^4$-(C_1-C_6)alkylene-S(=O)-R^5, -(C_0-C_6)alkylene-$S(=O)_2$-R^4, -O-(C_1-C_6)alkylene-$S(=O)_2$-R^4, $-NR^4$-(C_1-C_6)alkylene-$S(=O)_2$-R^5, -(C_0-C_6)alkylene-NR^4R^5, -O-(C_2-C_6)alkylene-NR^4R^5, $-NR^4$-(C_2-C_6)alkylene-NR^5R^6, -(C_0-C_6)alkylene-$S(=O)_2NR^4R^5$, -O-(C_1-C_6)alkylene-$S(=O)_2NR^4R^5$, $-NR^4$-(C_1-C_6)alkylene-$S(=O)_2NR^5R^6$, -(C_0-C_6)alkylene-NR^4-$S(=O)_2R^5$, -O-(C_2-C_6)alkylene-NR^4-$S(=O)_2R^5$, $-NR^4$-(C_2-C_6)alkylene-NR^5-$S(=O)_2R^6$, -(C_0-C_6)alkylene-C(=O)-NR^4R^5, -O-(C_1-C_6)alkylene-C(=O)-NR^4R^5, $-NR^4$-(C_1-C_6)alkylene-C(=O)-NR^5R^6, -(C_0-C_6)alkylene-NR^4C(=O)-R^5, -O-(C_2-C_6)alkylene-NR^4C(=O)-R^5, $-NR^4$-(C_2-C_6)alkylene-NR^5C(=O)-R^6, -(C_0-C_6)alkylene-OC(=O)-R^4, -O-(C_2-C_6)alkylene-OC(=O)-R^4, $-NR^4$-(C_2-C_6)alkylene-OC(=O)-R^5, -(C_0-C_6)alkylene-C(=O)-OR^4, -O-(C_1-C_6)alkylene-C(=O)-OR^4, -(C_0-C_6)alkylene-C(=O)-R^4, -O-(C_1-C_6)alkylene-C(=O)-R^4, $-NR^4$-(C_1-C_6)alkylene-C(=O)-R^5, -(C_0-C_6)alkylene-NR^4-C(=O)-OR^5, -C(=O)-(C_1-C_6)alkylene-NR^4-C(=O)-OR^5, -(C_0-C_6)alkylene-O-C(=O)-NR^4R^5, -(C_0-C_6)alkylene-NR^4-C(=O)-NR^5R^6, -O-(C_2-C_6)alkylene-NR^4-C(=O)-NR^5R^6, $-NR^4$-(C_2-C_6)alkylene-NR^5-C(=O)-NR^6R^7, -(C_0-C_6)alkylene-NR^4-C(=S)-NR^5R^6 and -(C_0-C_6)alkylene-NR^4-C(=NR^5)-NR^6R^7;

R^4, R^5, R^6 and R^7 are each independently hydrogen or an optionally substituted radical selected from the group of -(C_1-C_6)haloalkyl, -(C_1-C_6)alkyl, -(C_1-C_6)cyanoalkyl, -(C_3-C_7)cycloalkyl, -(C_1-C_6)alkylene-(C_3-C_7)cycloalkyl, heteroaryl, -(C_1-C_6)alkylene-heteroaryl, aryl, -(C_1-C_6)alkylene-heterocycle,

heterocycle, -(C_1-C_6)alkylene-aryl, -(C_0-C_6)alkylene-O-(C_0-C_6)alkyl, -(C_0-C_6)alkylene-N-((C_0-C_6)alkyl)$_2$ and -C(=O)-O-(C_1-C_6)alkyl;

Q represents an aryl or heteroaryl of formula:



wherein each aryl or heteroaryl ring is optionally substituted with n radicals B, wherein n is an integer equal to zero, 1, 2, 3, 4 or 5; wherein B^1 is a radical B;

the or each $(B)_n$ is independently selected from the group of hydrogen, halogen, -CN, -OH, -NO_2, -CF_3, -SH, -NH_2 and an optionally substituted radical selected from the group of -(C_1-C_6)alkyl, -(C_1-C_6)haloalkyl, -(C_2-C_6)alkynyl, -(C_2-C_6)alkenyl, -(C_3-C_7)cycloalkyl, -(C_1-C_6)alkylene-(C_3-C_7)cycloalkyl, -(C_3-C_8)cycloalkenyl, -(C_1-C_6)cyanoalkyl, -(C_1-C_6)alkylene-heteroaryl, -(C_1-C_6)alkylene-aryl, aryl, heteroaryl, -(C_1-C_6)alkylene-heterocycle, heterocycle, -(C_0-C_6)alkylene-OR^8, -O-(C_2-C_6)alkylene-OR^8, -NR^8(C_2-C_6)alkylene-OR^9, -(C_3-C_6)alkynylene-OR^8, -(C_3-C_6)alkynylene-NR^8R^9, -(C_3-C_6)alkenylene-OR^8, -(C_3-C_6)alkenylene-NR^8R^9, -(C_0-C_6)alkylene-S-R^8, -O-(C_2-C_6)alkylene-S-R^8, -NR^8-(C_2-C_6)alkylene-S-R^9, -(C_0-C_6)alkylene-S(=O)-R^8, -O-(C_1-C_6)alkylene-S(=O)-R^8, -NR^8-(C_1-C_6)alkylene-S(=O)-R^9, -(C_0-C_6)alkylene-S(=O)$_2$-R^8, -O-(C_1-C_6)alkylene-S(=O)$_2$-R^8, -NR^8-(C_1-C_6)alkylene-S(=O)$_2$-R^9, -(C_0-C_6)alkylene-NR^8R^9, -O-(C_2-C_6)alkylene-NR^8R^9, -NR^8-(C_2-C_6)alkylene-NR^9R^{10}, -(C_0-C_6)alkylene-S(=O)$_2$$NR^8R^9$, -O-($C_1$-$C_6$)alkylene-S(=O)$_2$$NR^8R^9$, -$NR^8$-($C_1$-$C_6$)alkylene-S(=O)$_2$$NR^9R^{10}$, -($C_0$-$C_6$)alkylene-$NR^8$-S(=O)$_2$$R^9$, -O-($C_2$-$C_6$)alkylene-$NR^8$-S(=O)$_2$$R^9$, -$NR^8$-($C_2$-$C_6$)alkylene-$NR^9$-S(=O)$_2$$R^{10}$, -($C_0$-$C_6$)alkylene-C(=O)-$NR^8R^9$, -O-($C_1$-$C_6$)alkylene-C(=O)-$NR^8R^9$, -$NR^8$-($C_1$-$C_6$)alkylene-C(=O)-$NR^9R^{10}$, -($C_0$-$C_6$)alkylene-$NR^8$C(=O)-$R^9$, -O-($C_2$-$C_6$)alkylene-$NR^8$C(=O)-$R^9$, -$NR^8$-($C_2$-$C_6$)alkylene-$NR^9$C(=O)-$R^{10}$, -($C_0$-$C_6$)alkylene-OC(=O)-$R^8$, -O-($C_2$-$C_6$)alkylene-OC(=O)-$R^8$, -$NR^8$-($C_2$-$C_6$)alkylene-OC(=O)-$R^9$, -($C_0$-$C_6$)alkylene-C(=O)-$OR^8$, -O-

$(C_1$-$C_6)$alkylene-C(=O)-OR^8, -NR^8-$(C_1$-$C_6)$alkylene-C(=O)-OR^9, -$(C_0$-$C_6)$alkylene-C(=O)-R^8, -O-$(C_1$-$C_6)$alkylene-C(=O)-R^8, -NR^8-$(C_1$-$C_6)$alkylene-C(=O)-R^9, -$(C_0$-$C_6)$alkylene-NR^8-C(=O)-OR^9, -$(C_0$-$C_6)$alkylene-O-C(=O)-NR^8R^9, -$(C_0$-$C_6)$alkylene-NR^8-C(=O)-NR^9R^{10}, -O-$(C_2$-$C_6)$alkylene-NR^8-C(=O)-NR^9R^{10}, -NR^8-$(C_2$-$C_6)$alkylene-NR^9-C(=O)-$NR^{10}R^{11}$, -$(C_0$-$C_6)$alkylene-NR^8-C(=S)-NR^9R^{10} and -$(C_0$-$C_6)$alkylene-NR^8-C(=NR^9)-$NR^{10}R^{11}$;

R^8, R^9, R^{10} and R^{11} are each independently hydrogen or an optionally substituted radical selected from the group of -$(C_1$-$C_6)$haloalkyl, -$(C_1$-$C_6)$alkyl, -$(C_1$-$C_6)$cyanoalkyl, -$(C_3$-$C_7)$cycloalkyl, -$(C_1$-$C_6)$alkylene-$(C_3$-$C_7)$cycloalkyl, heteroaryl, -$(C_1$-$C_6)$alkylene-heteroaryl, aryl, -$(C_1$-$C_6)$alkylene-heterocycle, heterocycle, -$(C_1$-$C_6)$alkylene-aryl, -$(C_0$-$C_6)$alkylene-O-$(C_0$-$C_6)$alkyl and -$(C_0$-$C_6)$alkylene-N-$((C_0$-$C_6)$alkyl$)_2$;

wherein optionally any two radicals A are combined with the intervening atoms to form a 3 to 10 membered bicyclic heterocycle, aryl or heteroaryl ring, wherein each ring is optionally further substituted with 1 to 5 radicals independently selected from the group of halogen, -CN, nitro, -$(C_1$-$C_6)$alkyl, -$(C_3$-$C_7)$alkyl, -$(C_0$-$C_6)$alkylene-O-$(C_0$-$C_6)$alkyl and -$(C_0$-$C_6)$alkylene-N-$((C_0$-$C_6)$alkyl$)_2$;


wherein optionally two of the substituents R^4, R^5, R^6 or R^7 are combined with the intervening atoms to form a 3 to 10 membered heterocycle, aryl or heteroaryl ring, wherein each ring is optionally further substituted with 1 to 5 radicals independently selected from the group of halogen, cyano, nitro, -$(C_1$-$C_6)$alkyl, -$(C_3$-$C_7)$alkyl, -$(C_0$-$C_6)$alkylene-O-$(C_0$-$C_6)$alkyl and –$(C_0$-$C_6)$alkylene-N-$((C_0$-$C_6)$alkyl$)_2$;

wherein optionally two substituents from R^8, R^9, R^{10} or R^{11} are combined with the intervening atoms to form a 3 to 10 membered heterocycle, aryl or heteroaryl ring, wherein each ring is optionally further substituted with 1 to 5 radicals independently selected from the group of halogen, cyano, nitro, -$(C_1$-$C_6)$alkyl, -$(C_3$-$C_7)$alkyl, -$(C_0$-$C_6)$alkylene-O-$(C_0$-$C_6)$alkyl and -$(C_0$-$C_6)$alkylene-N-$((C_0$-$C_6)$alkyl$)_2$; and


wherein optionally any two radicals B are combined with the intervening atoms to form a 3 to 10 membered bicyclic heterocycle, aryl or heteroaryl ring, wherein

each ring is optionally further substituted with 1 to 5 radicals independently selected from the group of halogen, -CN, nitro, -(C_1-C_6)alkyl, -(C_3-C_7)alkyl, -(C_0-C_6)alkylene-O-(C_0-C_6)alkyl and -(C_0-C_6)alkylene-N-((C_0-C_6)alkyl)$_2$.


2. The compound according to claim 1 having the Formula (I), wherein P represents a heteroaryl of formula:



wherein each radical is optionally substituted with m radicals A, wherein m is an integer equal to zero, 1, 2, 3 or 4; and/or wherein Q represents:



3. The compound according to any preceding claim having Formula (I), wherein Q represents an aryl or heteroaryl group of formula:



wherein each radical is optionally substituted with n radicals B, wherein n is an integer equal to zero, 1, 2, 3, 4 or 5.

4. The compound according to any preceding claim having the Formula (I), wherein:

the cycloalkyl, heterocycle, aryl and heteroaryl ring systems of $(A)_m$ are selected from the group of azetidinyl, 2-azabicyclo[2.2.1]heptan-2-yl, 7-azabicyclo[2.2.1]heptan-7-yl, benzimidazolyl, benzisothiazolyl benzisoxazolyl, benzofuryl, benzopyrazolyl, benzothiazolyl, benzothiophenyl, benzotriazolyl, benzoxazolyl, dihydrofuranyl, dihydrothienyl, dioxolanyl, 1,1-dioxo-thiomorpholinyl, furazanyl, furyl, imidazolidinyl, imidazolinyl, imidazolonyl, imidazolyl, imidazopyridazinyl, imidazopyridyl, indolyl, isoindolyl,

isoquinolinyl, isothiazolinyl, isothiazolyl, isoxazolidinyl, isoxazolinyl, isoxazolyl, morpholinyl, naphthyl, naphthyridinyl, oxadiazolyl, oxazolidinyl, oxazolinyl, oxazolonyl, oxazolopyridazinyl, oxazolopyridyl, oxazolyl, oxetanyl, phenyl, piperazinonyl, piperazinyl, piperidinonyl, piperidinyl, phthalazinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolopyridinyl, pyrazolyl, pyridazinyl, pyridonyl, pyridyl, pyrimidyl, pyrrolidinonyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinazolyl, quinolyl, quinoxalinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrotriazolopyridyl, tetrahydrotriazolopyrimidinyl, tetrazolyl, thiadiazolyl, thiazolidinyl, thiazolinyl, thiazolonyl, thiazolopyridazinyl, thiazolopyridyl, thiazolyl, thienyl, thiomorpholinyl, thionaphthyl, thiopyranyl, triazolinyl, triazinyl, triazolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl and cyclooctenyl and each ring of said ring system is optionally substituted independently with 1 to 4 substituents R^4, R^5, R^6 or R^7; and/or wherein:

the cycloalkyl, heterocycle, aryl and heteroaryl ring systems of $(B)_n$ are selected from the group of azetidinyl, 2-azabicyclo[2.2.1]heptan-2-yl, 7-azabicyclo[2.2.1]heptan-7-yl, benzimidazolyl, benzisothiazolyl benzisoxazolyl, benzofuryl, benzopyrazolyl, benzothiazolyl, benzothiophenyl, benzotriazolyl, benzoxazolyl, dihydrofuranyl, dihydrothienyl, dioxolanyl, 1,1-dioxo-thiomorpholinyl, furazanyl, furyl, imidazolidinyl, imidazolinyl, imidazolonyl, imidazolyl, imidazopyridazinyl, imidazopyridyl, indolyl, isoindolyl, isoquinolinyl, isothiazolinyl, isothiazolyl, isoxazolidinyl, isoxazolinyl, isoxazolyl, morpholinyl, naphthyl, naphthyridinyl, oxadiazolyl, oxazolidinyl, oxazolinyl, oxazolonyl, oxazolopyridazinyl, oxazolopyridyl, oxazolyl, oxetanyl, phenyl, piperazinonyl, piperazinyl, piperidinonyl, piperidinyl, phthalazinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolopyridinyl, pyrazolyl, pyridazinyl, pyridonyl, pyridyl, pyrimidyl, pyrrolidinonyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinazolyl, quinolyl, quinoxalinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrotriazolopyridyl, tetrahydrotriazolopyrimidinyl, tetrazolyl, thiadiazolyl, thiazolidinyl, thiazolinyl, thiazolonyl, thiazolopyridazinyl, thiazolopyridyl, thiazolyl, thienyl, thiomorpholinyl, thionaphthyl, thiopyranyl, triazolinyl, triazinyl, triazolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl,

cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl and cyclooctenyl and each ring of said ring system is optionally substituted independently with 1 to 4 substituents R^8, R^9, R^{10} or R^{11}.

5. The compound according to any preceding claim having the Formula (I), wherein:

the cycloalkyl, heterocycle, aryl and heteroaryl ring systems of R^4, R^5, R^6, R^7, R^8, R^9, R^{10} or R^{11} are selected from the group of azetidinyl, benzimidazolyl, benzisothiazolyl benzisoxazolyl, benzofuryl, benzopyrazolyl, benzothiazolyl, benzothiophenyl, benzotriazolyl, benzoxazolyl, dihydrofuranyl, dihydrothienyl, dioxolanyl, 1,1-dioxo-thiomorpholinyl, furazanyl, furyl, imidazolidinyl, imidazolinyl, imidazolonyl, imidazolyl, imidazopyridazinyl, imidazopyridyl, indolyl, isoindolyl, isoquinolinyl, isothiazolinyl, isothiazolyl, isoxazolidinyl, isoxazolinyl, isoxazolyl, morpholinyl, naphthyl, naphthyridinyl, oxadiazolyl, oxazolidinyl, oxazolinyl, oxazolonyl, oxazolopyridazinyl, oxazolopyridyl, oxazolyl, oxetanyl, phenyl, piperazinonyl, piperazinyl, piperidinonyl, piperidinyl, phthalazinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolopyridinyl, pyrazolyl, pyridazinyl, pyridonyl, pyridyl, pyrimidyl, pyrrolidinonyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinazolyl, quinolyl, quinoxalinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrotriazolopyridyl, tetrahydrotriazolopyrimidinyl, tetrazolyl, thiadiazolyl, thiazolidinyl, thiazolinyl, thiazolonyl, thiazolopyridazinyl, thiazolopyridyl, thiazolyl, thienyl, thiomorpholinyl, thionaphthyl, thiopyranyl, triazolinyl, triazinyl, triazolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl and cyclooctenyl and each ring of said ring system is optionally substituted with 1-5 radicals independently selected from hydrogen, halogen, -CN, nitro, -$(C_1$-$C_6)$alkyl, -$(C_0$-$C_6)$alkylene-O-$(C_0$-$C_6)$alkyl and -$(C_0$-$C_6)$alkylene-N-$((C_0$-$C_6)$alkyl$)_2$; and/or


wherein R^1 is hydrogen; and/or

wherein R^2 and R^3 are each independently selected from the group of hydrogen, methyl and halogen.

6. The compound according to any preceding claim having the Formula (I), wherein the or each $(A)_m$ is independently selected from the group of hydrogen, halogen, -CN, -OH, $-CF_3$ and an optionally substituted radical selected from the group of -$(C_1$-$C_6)$alkyl, -$(C_1$-$C_6)$haloalkyl, -$(C_3$-$C_7)$cycloalkyl, heterocycle, -$(C_0$-$C_6)$alkylene-OR^4, -O-$(C_2$-$C_6)$alkylene-OR^4, -$NR^4(C_2$-$C_6)$alkylene-OR^5, -$(C_0$-$C_6)$alkylene-NR^4R^5, -O-$(C_2$-$C_6)$alkylene-NR^4R^5, -NR^4-$(C_2$-$C_6)$alkylene-NR^5R^6, -$(C_0$-$C_6)$alkylene-C(=O)-NR^4R^5, -$(C_0$-$C_6)$alkylene-NR^4C(=O)-R^5, -$(C_0$-$C_6)$alkylene-C(=O)-OR^4 and -$(C_0$-$C_6)$alkylene-C(=O)-R^4; and/or wherein the or each $(B)_n$ is independently selected from the group of hydrogen, halogen, -CN, $-CF_3$, and an optionally substituted radical selected from the group of -$(C_1$-$C_6)$alkyl, -$(C_3$-$C_7)$cycloalkyl, aryl, heteroaryl, heterocycle, -$(C_0$-$C_6)$alkylene-OR^8, -$NR^8(C_2$-$C_6)$alkylene-OR^9, -$(C_0$-$C_6)$alkylene-NR^8R^9, -$(C_0$-$C_6)$alkylene-C(=O)-OR^8 and -$(C_0$-$C_6)$alkylene-C(=O)-R^8.

7. The compound according to any preceding claim having the Formula (I), wherein R^4, R^5 and R^6 are each independently hydrogen or -$(C_1$-$C_6)$alkyl; and/or wherein R^8 and R^9 are each independently selected from the group of hydrogen, -$(C_1$-$C_6)$haloalkyl, -$(C_1$-$C_6)$alkyl and -$(C_3$-$C_7)$cycloalkyl.


8. The compound according to any preceding claim having the Formula (II):



(II)

a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof or an *N*-oxide form thereof, wherein Z^1 is selected from C or N.


9. The compound according to claims 1 to 7 having the Formula (III):



(III)

a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof or an *N*-oxide form thereof, wherein X is N or C.


10. The compound according to any preceding claim having the Formula (IV):



(IV)

a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof or an *N*-oxide form thereof, wherein X is N or C, and Z^1 is C or N.


11. The compound according to claim 10 having the Formula (V):



(V)

a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof or an *N*-oxide form thereof;

or having the Formula (VI):



(VI)

a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof or an *N*-oxide form thereof.

12. The compound according to any preceding claim wherein:

R^2 is hydrogen, methyl or halogen;

R^3 is methyl;


the or each $(A)_m$ is independently selected from the group of hydrogen, halogen, $-CF_3$ and an optionally substituted radical selected from the group of $-(C_1\text{-}C_6)$alkyl, $-(C_1\text{-}C_6)$haloalkyl, $-(C_3\text{-}C_7)$cycloalkyl, heterocycle, $-(C_0\text{-}C_6)$alkylene-OR^4, $-O-(C_2\text{-}C_6)$alkylene-OR^4, $-(C_0\text{-}C_6)$alkylene-NR^4R^5, $-O-(C_2\text{-}C_6)$alkylene-NR^4R^5, $-NR^4-(C_2\text{-}C_6)$alkylene-NR^5R^6, $-(C_0\text{-}C_6)$alkylene-$C(=O)$-NR^4R^5, $-(C_0\text{-}C_6)$alkylene-$NR^4C(=O)$-R^5, $-(C_0\text{-}C_6)$alkylene-$C(=O)$-OR^4 and $-(C_0\text{-}C_6)$alkylene-$C(=O)$-R^4;

R^4, R^5 and R^6 are each independently hydrogen, $-(C_1\text{-}C_6)$alkyl, or $-(C_1\text{-}C_6)$haloalkyl;

the or each $(B)_n$ is independently selected from the group of hydrogen, halogen and an optionally substituted radical selected from the group of $-(C_1\text{-}C_6)$alkyl, heterocycle, $-(C_0\text{-}C_6)$alkylene-OR^8, $-NR^8(C_2\text{-}C_6)$alkylene-OR^9, $-(C_0\text{-}C_6)$alkylene-NR^8R^9, $-(C_0\text{-}C_6)$alkylene-$C(=O)$-OR^8 and $-(C_0\text{-}C_6)$alkylene-$C(=O)$-R^8; and


R^8 and R^9 are each independently hydrogen $-(C_1\text{-}C_6)$alkyl, $-(C_3\text{-}C_7)$cycloalkyl or $-(C_1\text{-}C_6)$haloalkyl.

13. The compound according to any preceding claim having the Formula (VII) or (VIII):



(VII)

or



(VIII)

a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof or an *N*-oxide form thereof.

14. The compound according to claim 12, wherein:

Z^1 is selected from C or N;

R^2 is hydrogen, methyl or halogen;

R^3 is methyl;

the or each $(A)_m$ is independently selected from the group of hydrogen, halogen, and an optionally substituted radical selected from the group of -(C_1-C_6)alkyl, heterocycle, -(C_0-C_6)alkylene-OR^4, -(C_0-C_6)alkylene-NR^4R^5, -O-(C_2-C_6)alkylene-NR^4R^5, -NR^4-(C_2-C_6)alkylene-NR^5R^6 and -(C_0-C_6)alkylene-C(=O)-OR^4;

R^4, R^5 and R^6 are each independently hydrogen, -(C_1-C_6)alkyl, or -(C_1-C_6)haloalkyl;

the or each $(B)_n$ is independently selected from the group of hydrogen, halogen and an optionally substituted radical selected from the group of -(C_1-C_6)alkyl, heterocycle and -(C_0-C_6)alkylene-OR^8; and


R^8 is hydrogen, -(C_1-C_6)alkyl, -(C_3-C_7)cycloalkyl or -(C_1-C_6)haloalkyl.


15. The compound according to any preceding claim, wherein the or each $(A)_m$ is independently selected from the group of hydrogen, halogen and -(C_0-C_6)alkylene-OR^4; for example wherein R^4 is -(C_1-C_6)alkyl; and/or wherein the or each $(B)_n$ is independently selected from the group of hydrogen, halogen, heterocycle, -(C_0-C_6)alkylene-OR^8, and -(C_1-C_6)alkyl; for example wherein R^8 is -(C_1-C_6)alkyl, -(C_1-C_6)haloalkyl or -(C_3-C_7)cycloalkyl.

16. The compound according to any one of claims 8, and 10 to 15, wherein Z^1 is selected from C or N, R^2 is hydrogen, methyl or halogen, and R^3 is methyl; the or each $(A)_m$ is independently selected from the group of hydrogen, fluorine and -O-methyl; and/or the or each $(B)_n$ is independently selected from the group of hydrogen, fluorine, methyl, heterocycle, -O-methyl, -O-(C_3-C_7)cycloalkyl, and O-CHF_2.

17. The compound according to claims 1 to 16, wherein the compound can exist as optical isomers, and wherein the compound is either a racemic mixture or one or both of the individual optical isomers.

18. The compound according to claims 1 to 17, wherein said compound is one or more selected from:





and a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof or an *N*-oxide form thereof.

19. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 18 and a pharmaceutically acceptable carrier and/or excipient.

20. A compound or composition according to any one of claims 1 to 19 for use in the treatment or prevention of a condition in a mammal affected or facilitated by the

modulatory effect of a mGlu7 allosteric modulator, such as a mGlu7 negative allosteric modulator.

21. A compound or composition according to any one of claims 1 to 19 for use in treating, preventing, ameliorating, controlling or reducing the risk of various neurological and psychiatric disorders associated with glutamate dysfunction in a mammal; for example wherein the treatment or prevention is affected or facilitated by the modulatory effect of a mGlu7 negative allosteric modulator.

22. A compound or composition for use according to claim 20, wherein the condition is one or more of a central nervous system disorder, an otic disease or disorder or a pain disorder,

for example wherein the central nervous disorder is an anxiety disorder such as agoraphobia, generalized anxiety disorder (GAD), obsessive-compulsive disorder (OCD), panic disorder, or post-traumatic stress disorder (PTSD);

for example wherein the central nervous system disorder is a psychotic disorder selected from the group of schizophrenia, delusional disorder, schizoaffective disorder, schizophreniform disorder and substance induced psychotic disorder;

for example wherein the otic disease and disorder is one or more of an inner ear impairment, age-related hearing impairment (presbycusis), Meniere's disease, sudden hearing loss, noise induced hearing loss, otitis media, autoimmune inner ear disease, acute tinnitus, chronic tinnitus, drug-induced hearing loss, hidden hearing loss, cisplatin-induced hearing loss, aminoglycosides-induced hearing loss, ototoxicity, central auditory processing disorder or vestibular disorder;

for example wherein the pain disorder is one or more of neuropathic pain, inflammatory pain, visceral pain, acute pain, chronic pain, severe pain, intractable pain, post-traumatic pain, post-operative pain, headache pain or cancer pain.

23. A compound or composition according to any one of claims 1 to 19 for use as a medicament.

24. Use of a compound according to any one of claims 1 to 19 in the manufacture of a medicament for the treatment or prevention as defined in any one of claims 20 to 23.